Acquired platelet GPVI receptor dysfunction in critically ill patients with sepsis

Area of Science:

• Hematology
• Immunology
• Critical Care Medicine

Background:

• Glycoprotein VI (GPVI) is a key platelet receptor for collagen, crucial for vascular integrity.
• Sepsis involves complex inflammatory responses impacting multiple organ systems, including platelet function.
• Understanding early molecular defects in sepsis is vital for improving patient outcomes.

Purpose of the Study:

• To investigate defects in platelet signaling, particularly via GPVI, in patients with sepsis.
• To determine if GPVI dysfunction is an early indicator of sepsis onset.
• To explore the potential of GPVI signaling as a diagnostic biomarker for sepsis.

Main Methods:

• Pilot study involving 15 sepsis patients assessed at ICU admission, day 5-7, and ICU discharge.
• Comprehensive platelet analyses using flow cytometry, aggregometry, and immunoblotting.
• Assessment of GPVI-mediated signaling, including Syk kinase and LAT phosphorylation.

Main Results:

• Platelet function was significantly reduced in all sepsis patients, most notably after GPVI stimulation.
• GPVI dysfunction was present in 14/15 patients at ICU admission, preceding thrombocytopenia.
• Sepsis platelets exhibited impaired GPVI-mediated signal transduction, failing to phosphorylate Syk or LAT.

Conclusions:

• Early onset of GPVI signaling defects occurs in sepsis, independent of platelet count.
• GPVI dysfunction may serve as an early diagnostic indicator for sepsis.
• Further prospective studies are needed to validate GPVI signaling as an early sepsis biomarker.